Effect of OTX-101, a Novel Nanomicellar Formulation of Cyclosporine A, on Corneal Staining in Patients With Keratoconjunctivitis Sicca
A Pooled Analysis of Phase 2b/3 and Phase 3 Studies
In the October 2019 issue of Cornea, one of the co-author's degrees was incorrect in the article on pages 1259–1265.1 Jodi Luchs, OD, should instead be listed as Jodi Luchs, MD.
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.
1. Malhotra R, Devries DK, Luchs J, et al. Effect of OTX-101, a novel nanomicellar formulation of cyclosporine A, on corneal staining in patients with keratoconjunctivitis sicca: a pooled analysis of phase 2b/3 and phase 3 studies. Cornea. 2019;38:1259–1265.